Literature DB >> 19252843

Scaling-up and production of therapeutic antibodies for preclinical studies.

Yang Feng1, Dimiter S Dimitrov.   

Abstract

Monoclonal antibodies are increasingly used for treatment of various diseases, mostly cancer therapy and auto-immune diseases. New chimeric, humanized, or fully-human antibodies specific to novel or already validated targets are being developed in many academic labs as well as in commercial entities. A validation of antibodies in preclinical settings is an important component of the road from discovery to clinic. Preparing sufficient amount of high-quality antibodies for preclinical studies is a challenge in some cases. This article summarizes protocols used in research laboratories, and is based on our own experience in the establishment of stable clones of CHO cells to scaling-up of tissue cultures for production of antibodies in bioreactors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19252843      PMCID: PMC3402213          DOI: 10.1007/978-1-59745-554-1_26

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  9 in total

Review 1.  Production of recombinant protein therapeutics in cultivated mammalian cells.

Authors:  Florian M Wurm
Journal:  Nat Biotechnol       Date:  2004-11       Impact factor: 54.908

2.  Influence of plasmid DNA topology on the transfection properties of DOTAP/DOPE lipoplexes.

Authors:  Katrien Remaut; Niek N Sanders; Farzaneh Fayazpour; Jozef Demeester; Stefaan C De Smedt
Journal:  J Control Release       Date:  2006-08-18       Impact factor: 9.776

3.  Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice.

Authors:  Mason X Zhang; M Charlotte Bohlman; Carol Itatani; Dennis R Burton; Paul W H I Parren; Stephen C St Jeor; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

4.  Production of human monoclonal antibody in eggs of chimeric chickens.

Authors:  Lei Zhu; Marie-Cecile van de Lavoir; Jenny Albanese; David O Beenhouwer; Pina M Cardarelli; Severino Cuison; David F Deng; Shrikant Deshpande; Jennifer H Diamond; Lynae Green; Edward L Halk; Babette S Heyer; Robert M Kay; Allyn Kerchner; Philip A Leighton; Christine M Mather; Sherie L Morrison; Zivko L Nikolov; David B Passmore; Alicia Pradas-Monne; Benjamin T Preston; Vangipuram S Rangan; Mingxia Shi; Mohan Srinivasan; Steven G White; Peggy Winters-Digiacinto; Susan Wong; Wen Zhou; Robert J Etches
Journal:  Nat Biotechnol       Date:  2005-08-28       Impact factor: 54.908

5.  Efficient expression of recombinant human monoclonal antibodies in Drosophila S2 cells.

Authors:  Daniel X Johansson; Katarina Drakenberg; Kathrin H Hopmann; Alexej Schmidt; Fayezeh Yari; Jorma Hinkula; Mats A A Persson
Journal:  J Immunol Methods       Date:  2006-09-25       Impact factor: 2.303

6.  A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies.

Authors:  Jiandong Li; Christian Menzel; Doris Meier; Congcong Zhang; Stefan Dübel; Thomas Jostock
Journal:  J Immunol Methods       Date:  2006-11-13       Impact factor: 2.303

7.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

Review 8.  Appropriate mammalian expression systems for biopharmaceuticals.

Authors:  R G Werner; W Noé; K Kopp; M Schlüter
Journal:  Arzneimittelforschung       Date:  1998-08

9.  Recombinant human antibodies: linkage of an Fab fragment from a combinatorial library to an Fc fragment for expression in mammalian cell culture.

Authors:  E Bender; J M Woof; J D Atkin; M D Barker; C R Bebbington; D R Burton
Journal:  Hum Antibodies Hybridomas       Date:  1993-04
  9 in total
  5 in total

1.  Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment.

Authors:  Taichi Kimura; Takeshi Kuwata; Satoshi Ashimine; Manabu Yamazaki; Chisako Yamauchi; Kanji Nagai; Akashi Ikehara; Yang Feng; Dimiter S Dimitrov; Seiichi Saito; Atsushi Ochiai
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

2.  Therapeutic Antibodies: An Overview.

Authors:  Gunnar Houen
Journal:  Methods Mol Biol       Date:  2022

3.  Near infrared photoimmunotherapy with an anti-mesothelin antibody.

Authors:  Tadanobu Nagaya; Yuko Nakamura; Kazuhide Sato; Yi-Fan Zhang; Min Ni; Peter L Choyke; Mitchell Ho; Hisataka Kobayashi
Journal:  Oncotarget       Date:  2016-04-26

4.  An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections.

Authors:  Ha V Dang; Yee-Peng Chan; Young-Jun Park; Joost Snijder; Sofia Cheliout Da Silva; Bang Vu; Lianying Yan; Yan-Ru Feng; Barry Rockx; Thomas W Geisbert; Chad E Mire; Christopher C Broder; David Veesler
Journal:  Nat Struct Mol Biol       Date:  2019-09-30       Impact factor: 15.369

5.  Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma.

Authors:  Yi-Fan Zhang; Mitchell Ho
Journal:  Sci Rep       Date:  2016-09-26       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.